SCHEMBL688244

SCHEMBL688244

O=c1ccc(-c2ccccn2)c[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.47
KDM4E B2RXH2 5/20 0.46
LMNA P02545 3/20 0.46
CCR1 P32246 2/20 0.46
CCR5 P51681 2/20 0.46
CCR8 P51685 2/20 0.46
CYP1A2 P05177 2/20 0.46
POLB P06746 1/20 0.46
METAP1 P53582 1/20 0.46
BLM P54132 1/20 0.46
HIF1A Q16665 1/20 0.46
DOHH Q9BU89 1/20 0.46
P4HTM Q9NXG6 1/20 0.46
PRMT5 O14744 2/20 0.43
WDR77 Q9BQA1 1/20 0.43
BTK Q06187 1/20 0.43
ATR Q13535 2/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13575374 0.79 ALDH1A1 (0.41) CYP2A6KDM4EATRL3MBTL1ALDH1A1
SCHEMBL14685050 0.78 KDM4E (0.46) CYP2A6KDM4ELMNACCR1CCR5
SCHEMBL11005639 0.76 PRMT5 (0.45) KDM4EPRMT5WDR77ATRL3MBTL1
SCHEMBL10843819 0.76 MAPT (0.46) ATRALDH1A1MAPTCYP2D6
SCHEMBL10845139 0.76 MAPT (0.49) ATRMAPTCYP2D6CYP19A1CYP2C9
SCHEMBL9231553 0.75 CA12 (0.49) CYP2A6KDM4ELMNAMETAP1PRMT5
SCHEMBL30989132 0.75 KDM4E (0.72) CYP2A6KDM4ELMNACCR1CCR5
SCHEMBL1566968 0.75 KDM4E (0.72) CYP2A6KDM4ELMNACCR1CCR5
SCHEMBL30989133 0.75 KDM4E (0.72) CYP2A6KDM4ELMNACCR1CCR5
SCHEMBL23480006 0.74 KDM4E (0.52) CYP2A6KDM4ELMNACCR1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118731225-A Method for measuring content of pirenzepine intermediate 海南葫芦娃药业集团股份有限公司 2024-10-01 CN claimed
EP-3768671-B1 SUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS PRMT5 INHIBITORS AURIGENE ONCOLOGY LTD (IN) 2024-05-22 EP claimed
CN-116930351-A Method for measuring related substances of key starting materials of pirenzepine by HPLC 上海现代制药股份有限公司 2023-10-24 CN claimed
CN-116396212-B Preparation method of high-purity pirenzenenaphthalene intermediate 天津辰欣药物研究有限公司 2023-09-01 CN claimed
CN-116396212-A Preparation method of high-purity pirenzenenaphthalene intermediate 天津辰欣药物研究有限公司 2023-07-07 CN claimed
US-11542275-B2 Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2023-01-03 US claimed
CN-109799298-B Detection method of related substances in Perampanel bulk drug 南京海纳医药科技股份有限公司 2022-01-07 CN claimed
US-20190091156-A1 MILRINONE CONTROLLED-RELEASE FORMULATION Baker Heart and Diabetes Institute (AU) 2019-03-28 US claimed
US-20170348292-A1 METHOD OF TREATMENT Baker Heart and Diabetes Institute (AU) 2017-12-07 US claimed
EP-3236963-A1 METHOD OF TREATMENT Cardiora Pty Ltd (AU) 2017-11-01 EP claimed
EP-2744496-A1 CONTROLLED-RELEASE FORMULATION Baker IDI Heart and Diabetes Institute Holdings Ltd (AU) 2014-06-25 EP claimed
EP-2123639-B1 PROCESS FOR PRODUCTION OF 2,3'-BIPYRIDYL-6'-ONE FUJIFILM FINECHEMICALS CO LTD (JP) 2014-03-26 EP claimed
WO-2013023250-A1 CONTROLLED-RELEASE FORMULATION BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LIMITED (AU) 2013-02-21 WO claimed
US-20100016603-A1 PRODUCTION PROCESS OF 2,3'-BIPYRIDYL-6'-ONE FUJIFILM FINECHEMICALS CO., LTD. (JP) 2010-01-21 US claimed
EP-2123639-A1 PROCESS FOR PRODUCTION OF 2,3'-BIPYRIDYL-6'-ONE Fujifilm Finechemicals Co. Ltd. (JP) 2009-11-25 EP claimed
EP-1553086-B1 PROCESS FOR PRODUCING 5-(2 '-PYRIDYL)-2-PYRIDONE DERIVATIVE KURARAY CO (JP) 2009-10-07 EP claimed
US-7524967-B2 Process for producing 5-(2′-pyridyl)-2-pyridone derivative KURARAY CO., LTD. (JP) 2009-04-28 US claimed
US-20060004205-A1 Process for producing 5-(2'-pyridyl)-2-pyridone derivative KURARAY CO. LTD. (JP) 2006-01-05 US claimed
EP-1553086-A1 PROCESS FOR PRODUCING 5-(2 -PYRIDYL)-2-PYRIDONE DERIVATIVE Kuraray Co., Ltd. (JP) 2005-07-13 EP claimed
EP-0127756-A1 Process for the preparation of 5-pyridyl-pyridine-2(1H)-ones FABRICA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS ABELLO, S.A. (ES) 1984-12-12 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190091156-A1 MILRINONE CONTROLLED-RELEASE FORMULATION SIRT5, TNNI3, PROC CYP2A6 363/4885KDM4E 3421/4885LMNA 1121/4885
US-11542275-B2 Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors PRMT5, PRMT1, PRMT8 CYP2A6 4121/4885KDM4E 59/4885LMNA 3013/4885
US-20100016603-A1 PRODUCTION PROCESS OF 2,3'-BIPYRIDYL-6'-ONE AMPD2, PARP12, MRPL21 CYP2A6 284/4885KDM4E 992/4885LMNA 4248/4885
US-20060004205-A1 Process for producing 5-(2'-pyridyl)-2-pyridone derivative PNPO, PDXK, CYP2B6 CYP2A6 23/4885KDM4E 674/4885LMNA 3610/4885
US-20170348292-A1 METHOD OF TREATMENT TNNI3, NPPA, TNNT2 CYP2A6 1573/4885KDM4E 2704/4885LMNA 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.